Cat. No.: DAB-0012197
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu734 of human IRP1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ACO1 |
| UniProt No. | P21399 |
| Gene ID | 48 |
| Gene Description | Iron regulatory proteins are RNA-binding proteins that recognize iron-responsive elements and play an important role in maintaining iron homeostasis in mammalian cells. IREs are conserved cis-regulatory hairpin structures located within the 5’ or 3’ untranslated regions of target mRNAs. IRPs inhibit translation when bound to IREs within the 5’ UTR of mRNA encoding for proteins involved in iron storage, export, and utilization. IRP binding to multiple IREs within the 3’ UTR of transferin receptor 1 mRNA prevents its degradation, thereby augmenting translation of TFR1 and increasing iron uptake into cells. Dysregulation of IRPs has been associated with human cancers.IRP1 is a bifunctional protein. In iron replete cells, IRP1 is associated with a 4Fe-4S cluster that keeps IRP1 in a closed conformation, and functions as a cytosolic aconitase catalyzing the conversion of citrate into iso-citrate. In iron deficient cells, IRP1 loses the 4Fe-4S cluster and adopts an open structure with IRE-binding activity. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
